Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective,

Slides:

Advertisements

Similar presentations

Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice Lysanne.

Advertisements

Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial Renato Seracchioli, M.D., Mohamed.

Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and a meta-analysis Konstantinos A. Toulis, M.D.,

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study Jeff G. Wang, M.D., Richard A. Anderson,

Soyoung Bae, M.D., Joseph Karnitis, M.D. Fertility and Sterility

Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women Babak Mokhlesi, M.D.,

Fernando Zegers-Hochschild, M.D. Fertility and Sterility

Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D

Michael M. Alper, M.D. Fertility and Sterility

Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters Enrico Carmina, M.D., Francesco.

Michal Youngster, M. D. , Valerie L. Ward, M. D. , M. P. H. , Emily A

Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials Ana Cobo, Ph.D., César Diaz, M.D.

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome

Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome

Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study Nicole Hope, M.B., B.S., Hon., Luk.

Comparison of fallopian tube sperm perfusion and intrauterine tuboperitoneal insemination: a prospective randomized study Leonidas Mamas, M.D., Ph.D.

Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study Angela Kerchner, B.A., Whitney Lester,

Evaluation of the immature human oocytes from unstimulated cycles in polycystic ovary syndrome patients using a novel scoring system Shan Liu, M.D.,

Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature.

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

Medical treatment of ectopic pregnancy: a committee opinion

Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary.

Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F

Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization Ginny Mounce,

Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral.

Evolutionary determinants of polycystic ovary syndrome: part 1

The effects of oral contraceptives including low-dose estrogen and drospirenone on the concentration of leptin and ghrelin in polycystic ovary syndrome

Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular.

Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized.

Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic.

Epidemiology and Adverse Cardiovascular Disease (CVD) Risk Profile of Polycystic Ovarian Syndrome (PCOS): The Kaiser Permanente Polycystic Ovarian Syndrome.

Mieke Carine Wim Eeckhaut, Ph.D. Fertility and Sterility

Raising threshold for diagnosis of polycystic ovary syndrome excludes population of patients with metabolic risk Molly M. Quinn, M.D., Chia-Ning Kao,

Cardiovascular risk in normal weight, eumenorrheic, nonhirsute daughters of patients with polycystic ovary syndrome: a pilot study Cesare Battaglia,

Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced.

Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.

Hyperglycemia Stimulates Activation of Nuclear Factor κB (NFκB) in Mononuclear Cells (MNC) of Women With Polycystic Ovary Syndrome (PCOS) F. Gonzalez,

Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,

Laparoscopically assisted uterovestibular anastomosis in patients with uterine cervix atresia and vaginal aplasia Luigi Fedele, M.D., Stefano Bianchi,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study Carlo.

Increased secretion of amylin in women with polycystic ovary syndrome

Veronica Bertini, Ph. D. , Angelo Valetto, Ph. D. , Angela Uccelli, Ph

Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial Renato Seracchioli, M.D., Mohamed.

Prospective cohort study of three- versus two-dimensional ultrasound for prediction of oocyte maturity Doron Shmorgun, M.D., Edward Hughes, M.D., Patrick.

Fleur R. Cattrall, M. B. B. S. , Beverley J. Vollenhoven, M. B. B. S

Metformin treatment before and during in vitro fertilization or intracytoplasmic sperm injection in women with polycystic ovary syndrome: summary of a.

Michael C. Allemand, M. D. , Ian S. Tummon, M. D. , Jennifer L. Phy, D

Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment Richard Fleming, Ph.D.,

Banu Ucar, M. D. , Volkan Noyan, M. D. , Osman Caglayan, M. D

Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial Antoni J. Duleba, M.D.,

Cameron Gilbert, M. Sc. , Maria Valois, M. D. , FRCPC, Ph. D

Impact of laparoscopic ovarian drilling on anti-Müllerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women.

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Prospective, randomized comparison between raloxifene and clomiphene citrate for ovulation induction in polycystic ovary syndrome Ernesto de Paula Guedes.

Fertility and Sterility: an evaluation

Paolo Moghetti, M.D. Fertility and Sterility

Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome:

Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with.

Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome Yuwen Wu, M.D., Jianhua Zhang,

Inappropriate gonadotropin secretion in polycystic ovary syndrome

Tsan-Hon Liou, M. D. , Ph. D. , Jen-Hung Yang, M. D. , Ph. D

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

Increased risk of depressive disorders in women with polycystic ovary syndrome Elizabeth Hollinrake, B.S., Alison Abreu, M.D., Michelle Maifeld, R.N.C.,

Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome Kevin H. Maas, M.D., Ph.D., Sandy Chuan,

Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization Ginny Mounce,

Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels

Is there a role for diet in ameliorating the reproductive sequelae associated with chronic low-grade inflammation in polycystic ovary syndrome and obesity?

Presentation transcript:

Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study Cesare Battaglia, M.D., Ph.D., Fulvia Mancini, M.D., Ph.D., Raffaella Fabbri, B.D., Nicola Persico, M.D., Paolo Busacchi, M.D., Fabio Facchinetti, M.D., Stefano Venturoli, M.D. Fertility and Sterility Volume 94, Issue 4, Pages 1417-1425 (September 2010) DOI: 10.1016/j.fertnstert.2009.05.044 Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Brachial artery ultrasound and Doppler analyses. Upper panel: 15 seconds after reactive hyperemia, in basal conditions and after treatment, the percentage change in the brachial artery diameter was similar in Yasmin- and in NuvaRing-treated patients with PCOS. At 120 seconds, hyperemia was still present. Its results were similar in both groups. Lower panel: 15 seconds after reactive hyperemia, in basal conditions and after treatment, the percentage change in brachial artery PI was similar in Yasmin- and in NuvaRing-treated patients with PCOS. At 120 seconds, hyperemia was still present. No significant differences were observed between the groups. Fertility and Sterility 2010 94, 1417-1425DOI: (10.1016/j.fertnstert.2009.05.044) Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Total cholesterol/LDL (upper panel) and HDL/LDL (lower panel) ratios were unchanged after 6 months of therapy with Yasmin (group I) or with NuvaRing (group II). Fertility and Sterility 2010 94, 1417-1425DOI: (10.1016/j.fertnstert.2009.05.044) Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions